Mirati Therapeutics (MRTX)

$214.47 0.72 (0.34%)

16:19 EST MRTX Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 6.91B

PE Ratio -83.68

EPS -2.562953

Volume (Avg. Vol.) 444,300

Day's Range 211.20 - 216.94

52-Week Range 66.01 - 249.42

Dividend & Yield N/A (N/A)

MRTX Stock Predictions, Articles, and Mirati Therapeutics News

From InvestorPlace
From the Web

7 Biotech Stocks To Buy Beyond Covid Vaccine Plays

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Dec 14, 2020

It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

The 10 Best Stocks for 2019 — So Far

By James Brumley, InvestorPlace Feature Writer Jun 4, 2019

Roku, Array Biopharma and Guardant Health are just some of the best stocks by returns for the first half of 2019.

Pre-earnings Bullish Momentum Pattern and Trigger in Mirati Therapeutics Inc

From Capital Market Laboratories Jan 14, 2021

The Techncial Trigger Driven Stock Trade in Mirati Therapeutics Inc (NASDAQ:MRTX) .

15 Stocks Moving In Tuesday's After-Hours Session

From Benzinga Jan 12, 2021

Gainers Axcelis Technologies (NASDAQ: ACLS) shares are trading higher after the company raised Q4 guidance and reported a $100 million buyback. DermTech (NASDAQ: DMTK) shares are...

Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe

From Zacks Investment Research Dec 23, 2020

The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Stocks That Hit 52-Week Highs On Monday

From Benzinga Dec 14, 2020

Monday's morning session saw 240 companies set new 52-week highs. Key Facts: The largest company by market cap to set a new 52-week high was PayPal Holdings (NASDAQ:...

Piper Says Mirati Now 'Prime' Biotech Takeout Candidate, Boosts Target

From Talk Markets Nov 5, 2020

Piper Sandler analyst Tyler Van Buren raised the firm's price target on Mirati Therapeutics to $260 from $210 and keeps an Overweight rating on the shares.

Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer

From Zacks Investment Research Dec 17, 2020

The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

A

Strong Buy